- Home
- CATX vs INNV Comparison
CATX vs INNV Comparison
Compare CATX & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- INNV
- Stock Information
- Founded
- CATX 1983
- INNV 2007
- Country
- CATX United States
- INNV United States
- Employees
- CATX N/A
- INNV N/A
- Industry
- CATX Medical/Dental Instruments
- INNV Medical/Nursing Services
- Sector
- CATX Health Care
- INNV Health Care
- Exchange
- CATX Nasdaq
- INNV Nasdaq
- Market Cap
- CATX 239.0M
- INNV 527.9M
- IPO Year
- CATX N/A
- INNV 2021
- Fundamental
- Price
- CATX $3.97
- INNV $4.07
- Analyst Decision
- CATX Strong Buy
- INNV Sell
- Analyst Count
- CATX 11
- INNV 2
- Target Price
- CATX $12.90
- INNV $5.00
- AVG Volume (30 Days)
- CATX 1.3M
- INNV 46.1K
- Earning Date
- CATX 08-11-2025
- INNV 09-09-2025
- Dividend Yield
- CATX N/A
- INNV N/A
- EPS Growth
- CATX N/A
- INNV N/A
- EPS
- CATX N/A
- INNV N/A
- Revenue
- CATX $1,471,000.00
- INNV $831,683,000.00
- Revenue This Year
- CATX N/A
- INNV $13.77
- Revenue Next Year
- CATX N/A
- INNV $10.12
- P/E Ratio
- CATX N/A
- INNV N/A
- Revenue Growth
- CATX N/A
- INNV 12.19
- 52 Week Low
- CATX $1.60
- INNV $2.60
- 52 Week High
- CATX $16.55
- INNV $6.69
- Technical
- Relative Strength Index (RSI)
- CATX 61.19
- INNV 52.67
- Support Level
- CATX $3.33
- INNV $4.13
- Resistance Level
- CATX $3.69
- INNV $4.41
- Average True Range (ATR)
- CATX 0.38
- INNV 0.24
- MACD
- CATX 0.01
- INNV 0.01
- Stochastic Oscillator
- CATX 64.23
- INNV 55.17
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.